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Abstract
Background: Lassa virus (LASV) infection causes an acute and sometimes fatal hemorrhagic disease in humans and
nonhuman primates; however, little is known about the development of Lassa fever. Here, we performed a pilot
study to begin to understand the progression of LASV infection in nonhuman primates.
Methods: Six cynomolgus monkeys were experimentally infected with LASV. Tissues from three animals were
examined at an early- to mid-stage of disease and compared with tissues from three animals collected at terminal
stages of disease.
Results: Dendritic cells were identified as a prominent target of LASV infection in a variety of tissues in all animals
at day 7 while Kupffer cells, hepatocytes, adrenal cortical cells, and endothelial cells were more frequently infected
with LASV in tissues of terminal animals (days 13.5-17). Meningoencephalitis and neuronal necrosis were
noteworthy findings in terminal animals. Evidence of coagulopathy was noted; however, the degree of fibrin
deposition in tissues was less prominent than has been reported in other viral hemorrhagic fevers.
Conclusion: The sequence of pathogenic events identified in this study begins to shed light on the development
of disease processes during Lassa fever and also may provide new targets for rational prophylactic and
chemotherapeutic interventions.
Introduction
Lassa fever (LF) is a severe hemorrhagic fever (HF) that is
endemic in West African countries with the highest inci-
dence in the Republic of Guinea, Sierra Leone, Liberia,
and Nigeria. It is estimated that Lassa virus (LASV)
infects over 300,000 individuals per year across this
region, causing over 3,000 deaths [1]. The case fatality
rate for LF is estimated to be approximately 15% in hos-
pitalized patients and has been reported to be greater
than 50% in several outbreaks [1,2]. Human infection is
associated with contact with a widely distributed and
highly commensal rodent, Mastomys natalensis,o rb y
contact with infected patients. Recent importation of LF
into Germany, the Netherlands, the United Kingdom,
and the United States by travelers on commercial airlines
[3-9] illustrates the potential for the spread of this highly
dangerous and contagious pathogen. In addition, LASV
has gained notoriety because it is classified as a Category
A bioweapon agent [10].
Currently, there are no vaccines or antiviral drugs
approved for LF. Treatment with intravenous ribavirin was
shown to reduce mortality from LF in high-risk patients
and presumably decreases morbidity in all patients with
LF [11,12]. However, the availability of ribavirin is very
limited in endemic areas and the effectiveness of treatment
is limited if not initiated within the first week of disease
onset [11,12]. Preventing contact with the reservoir host in
endemic areas is currently unachievable. Because adequate
and well-controlled clinical studies in humans cannot be
ethically conducted and as field efficacy studies are not yet
feasible for LF, licensure of any of these countermeasures
must be carried out under the U.S. Food and Drug
Administration (FDA) “Animal Efficacy Rule. This policy
was implemented in 2002 and allows for the evaluation of
vaccines or therapeutics using data derived from studies
carried out in an animal model that accurately reflects the
disease observed in humans. Importantly, the animal
model must be well-characterized and the pathophysiology
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disease in humans.
Currently, there is no immunocompetent mouse
model for LASV. Strain 13 guinea pigs are susceptible
to a strain of LASV (Josiah) from Sierre Leone with uni-
form mortality 15-19 days following i.m. inoculation
[13]. While guinea pigs are useful for screening vaccines
and antiviral drugs the disease caused by LASV infection
does not faithfully reproduce the human condition [14].
Several primate species have been evaluated as potential
models for LF including squirrel monkeys, capuchin
monkeys, marmosets, hamadryas baboons, African green
monkeys, cynomolgus monkeys and rhesus monkeys
[15-34]. While capuchin and squirrel monkeys serocon-
verted after LASV challenge both species were uniformly
resistant to lethal disease [14,16]. Interestingly, low chal-
lenge doses (10-15 pfu) of the Josiah strain of LASV
produce uniformly lethal disease in African green mon-
keys and rhesus macaques whereas high challenge doses
(1.2 × 10^6 pfu) produce only partially lethal infections
[14]. This same phenomenon was not observed in cyno-
molgus macaques [14] which appear to be more suscep-
tible to lethal LASV infection than these other species.
Most studies have used cynomolgus or rhesus monkeys
as a model to evaluate vaccines and/or treatments against
LF [17,18,21,22,27,29-31], while several studies have eval-
uated the pathogenesis of LF infection in macaques
[19,20,23-25,34]. However, with few exceptions, previous
investigations examined tissues of infected animals
euthanized when moribund, and shed little light on the
pathogenesis of LF infection during times before death.
The aim of this pilot study was to begin to characterize
the earlier stages of LF in a relevant nonhuman primate
model of human disease.
Materials and methods
Animals and inoculations
Six healthy, LASV-seronegative, cynomolgus (Macaca
fascicularis) macaques (3 to 4 kg) were used for these
studies. Animals were inoculated in the caudal thigh with
a calculated dose of 3000 plaque forming units (PFU) of
LASV (Josiah strain). Longitudinal blood samples were
collected before challenge and on days 3, 6 (herein
referred to as the actual closer time of 5.5 days), 10, and
14 (herein referred to as the actual closer time of 13.5
days) after challenge and analyzed by complete blood
counts, clinical chemistry, coagulation assays, and fluor-
escence-activated cells sorter analysis of various cell
populations (described below). In addition, blood samples
were collected at the time of euthanasia. Each monkey
was specifically evaluated for anorexia, diarrhea, nasal
exudates, vomiting, conjunctivitis, cutaneous rash, dehy-
dration, central nervous system disturbances, reduced
activity, and hemorrhage using a subjective scoring
system. Three animals were euthanized on day 7 after
LASV challenge while the remaining three animals were
euthanized when clinical signs indicated terminal disease
according to an endpoint scoring sheet.
Hematology
Total white blood cell counts, white blood cell differen-
tials, red blood cell counts, platelet counts, hematocrit
values, total hemoglobin, mean cell volume, mean corpus-
cular volume, and mean corpuscular hemoglobin concen-
tration were determined from blood samples collected in
tubes containing EDTA, using a laser-based hematologic
analyzer (Coulter Electronics, Hialeah, FL).
Serum biochemistry and coagulation assays
Concentrations of albumin (ALB), amylase (AMY), alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
alkaline phosphatase (ALP), gamma-glutamyltransferase
(GGT), glucose (GLU), cholesterol (CHOL), total protein
(TP), total bilirubin (TBIL), urea nitrogen (BUN), and crea-
tinine (Cr) were measured using a Piccolo Point-Of-Care
Blood Analyzer (Abaxis, Sunnyvale, CA). Plasma levels of
fibrin degradation products (D-dimers) were quantitated
by an enzyme-linked immunosorbent assay (ELISA)
according to manufacturer’s directions (“Asserachrom D-
D”, Diagnostica Stago, Inc., Parsippany, NJ). Plasma levels
of protein C were determined by a chromatic hydrolysis
assay (DiaPharma, West Chester, OH) as described
elsewhere [35].
Cytokine/chemokine production
Cytokine/chemokine levels in monkey plasma were
assayed using a human cytokine multiplex-25 bead
array assay kit (BioSource, Camarillo, CA) for the Bio-
Plex 200 System (Bio-Rad, Hercules, CA) according to
manufacturer’s directions. Cytokines/chemokines
assayed included eotaxin, granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), interferon (IFN)-a,
IFN-g,I L - 1 b, IL-1 receptor antagonist (IL-1RA), IL-2,
IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40/p70,
IL-13, IL-15, IL-17, IFN-g-inducing protein (IP)-10,
monocyte chemoattractant protein (MCP)-1, macro-
phage inflammatory protein (MIP)-1a,M I P - 1 b, mono-
kine induced by g-IFN (MIG), regulated upon activation
normal T-cell expressed and secreted (RANTES), and
tumor necrosis factor (TNF)-a.
Histology
A complete necropsy was performed on all animals.
Tissues were collected and immersion-fixed in 10%
neutral-buffered formalin and processed for histo-
pathology and phosphotungstic acid hematoxylin
(PTAH) staining to demonstrate polymerized fibrin as
previously described [35].
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Tissue sections were deparaffinized and rehydrated
through a series of graded ethanols, pretreated with
DAKO Ready to Use Proteinase K (DAKO, Carpinteria,
CA) for 6 minutes at room temperature, and blocked with
DAKO’s Serum Free Protein Block for 20 minutes before
exposure to antibody. Sections were incubated with pri-
mary antibody overnight a 4°C using a mouse monoclonal
antibody against LASV GP2 (USAMRIID, L52-121-22-
BA02) (1:4000). Sections were then exposed to a peroxi-
dase- or alkaline phosphatase-labeled polymer (Envision™,
DAKO Corp., Carpenteria, CA) for 30 minutes. Color
development was attained by exposing tissue to one of
three substrate-chromagens, either 3,3’-diaminobenzidine
(DAB) for 5 min; or 6-bromo-2-hydroxyl-3-naphtholic
acid (Histomark Red, Kirkegaard and Perry, Gaithersburg,
MD) for 50 minutes in the dark; or DAKO Permanent
Red for 50 minutes in the dark. Sections were counter-
stained with hematoxylin. Negative controls included
replicate sections exposed to anti-LASV virus antibodies
and unexposed cynomolgus monkey tissue; archived
LASV-infected cynomolgus tissue served as positive
controls.
Terminal Deoxynucleotidyl Transferase-Mediated
Deoxyuridine Triphosphate Nick End Labeling (TUNEL)
staining
The ApopTag detection kit (S7100 kit; Chemicon, Biller-
ica, MA) was used to detect cells undergoing apoptosis
in the spleen, lymph nodes, and liver. Sections were
stained in accordance with kit instructions with the fol-
lowing modifications; a 13-minute room temperature
protein digestion in prediluted proteinase K (DAKO)
was used. Slides were incubated in equilibration buffer
for 5 minutes, followed by incubation in working
strength terminal deoxynucleotidyl transferase (TdT)
enzyme at 37°C for 60 minutes. This was followed by a
stop/wash step and an anti-digoxigenin peroxidase step,
which were identical to kit instructions. Color develop-
ment was with DAB chromagen and then slides were
counterstained with hematoxylin.
Virus isolation
Infectious virus in EDTA plasma was assayed by counting
plaques on Vero cells maintained as monolayers in 6-well
plates under agarose, as previously described [31]. Portions
of liver; spleen; lung; kidney; adrenal gland; pancreas;
heart; ovary; brain; femoral bone marrow; and mandibular,
mesenteric, axillary, and inguinal lymph nodes were asep-
tically collected during necropsy and stored at -70°C until
assayed for infectious LASV. After thawing, tissues were
weighed and ground by mortar and pestle with alundum
in 5 ml of EMEM with Earl’s salts with 10% fetal calf
serum. Tissue homogenates were centrifuged at 10,000 ×
g for 15 minutes and viral titers were determined as
detailed above.
Statistical analysis
Student’s t test was used to compare cytokine/chemokine
values in pre-challenge versus post-challenge samples.
Statistical significance was assumed when p < 0.05.
Results
Clinical illness
Clinical findings are presented in Table 1. The first signs
of clinical illness were noticed at day 3 when four of the
six (4/6) animals given physical examinations had fevers
(defined as temperature over 103°F). Bleeding at the veni-
puncture site was noted in 1/3 animals at day 7 and 2/3
animals at day 10. Mild dehydration (approximately 5% as
evaluated subjectively by skin-fold retraction) was
observed in 3/3 animals by day 10. All three remaining
animals on day 10 were anorexic and showed signs of
mild to moderate depression. By day 13.5, clinical illness
progressed with animals becoming more anorexic and
dehydrated. One animal developed neurologic symptoms
including convulsions as well as seizures which increased
in length and severity; this animal was euthanized on day
13.5. Facial edema and epistaxis were noted in 1/2 remain-
ing animals by days 15-17. The two remaining animals
were euthanized at days 15 and 17, respectively, using a
subjective scoring system.
Hematology, clinical chemistry, and coagulation
There was a pronounced lymphopenia as lymphocytes
dropped from approximately 59% of the leukocyte popula-
tion just prior to LASV challenge (day 0) to less than 25%
on day 3, and then appeared to slightly rebound to approxi-
mately 40% by day 10 (Figure 1). Although still within nor-
mal reference range, circulating platelet numbers declined
from a mean of 392 × 10*/mm* (range 100-700 × 10*/
mm*) before LASV challenge (day 0) to 205 × 10*/mm* on
day 10 (Figure 1). However, by day 13.5, platelet numbers
returned to pre-challenge levels (mean 414 × 10*/mm*).
Development of fibrin degradation products (D-dimers)
showed increases of 12-fold by day 7 and near 20-fold by
day 10 (Figure 1). Plasma levels of protein C remained
unchanged at day 3 but decreased by approximately 25% at
days 7 and 10 (Figure 1).
Early serum enzyme levels were unremarkable, but many
were elevated during the late stages of disease. On day 10,
aspartate aminotransferase (AST) increased nearly 3-fold
(mean, 97 IU/L) as did alanine aminotransferase (ALT)
(mean, 69 IU/L) by day 13.5 (Figure 2). Blood urea nitrogen
(BUN) levels remained generally within normal limits
through day 10 and increased nearly 2-fold over baseline
on day 13.5 (Figure 2). Serum albumin levels slightly
decreased from a pre-LASV challenge mean of 3.0 g/dL to
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substantially fluctuate durin gt h ec o u r s eo fi n f e c t i o n .
Necropsy findings
At day 7, axillary and inguinal lymphadenopathy and
congestion were observed in all three animals (3/3)
euthanized at this time point. The mandibular and
mesenteric lymph nodes were also enlarged (3/3) and
noticeable enlargement and congestion of the iliac lymph
nodes was noted in one of the day 7 macaques. Addi-
tional findings at day 7 included friable spleens (1/3) and
congestion at the ileocecal junction (1/3). By terminal
time points (days 13.5-17), similar congestion and enlar-
gement of the inguinal, axillary, mandibular, and mesen-
teric lymph nodes (Figure 3A) were also suggestive of
LASV infection in all terminal animals (3/3). Other
noteworthy findings at days 13.5-17 included: congested
or pale yellow, friable livers (3/3) (Figure 3C); adrenal
gland enlargement (1/3); pancreas enlargement (1/3);
renal congestion (1/3); accumulation of red-tinged fluid
in the pericardial sac (2/3) (Figure 3B); congestion at the
ileocecal junction (1/3) (Figure 3E); and petechial hemor-
rhage on the mucosal surface of the urinary bladder (1/3)
(Figure 3D).
Virus titers in blood and tissues
The onset of plasma viremia occurred in four of six
(4/6) animals on day 3 and in all animals (6/6) by day
5.5. Peak viremia (mean 5.0 log10 pfu/ml) occurred on
day 13.5 (Figure 4). Infectious LASV was detected in
all tissues except the pancreas of all day 7 animals
(3/3) (Figure 4). The highest mean LASV titers at day
7 were detected in spleen and lymph nodes (6.3-7.0
log10 pfu/g) (Figure 4) suggesting that these organs are
early sites of viral replication. By terminal time points (days
13.5-17) virus was detected in all tissues of all three term-
inal animals. The highest mean titers from these terminal
animals were documented in the liver (7.7 log10 pfu/g),
followed by adrenal gland (7.2 log10 pfu/g), and spleen
(6.9 log10 pfu/g) (Figure 4).
Analysis of cytokines/chemokines in circulation
In order to evaluate the immune response to LASV infec-
tion, plasma and/or sera were analyzed for levels of cyto-
kines/chemokines. Significant increases (p < 0.05) in levels
of MCP-1 were detected at days 3, 5.5, 7, 10, and 13.5
while significant increases in levels of eotaxin were
observed at days 3, 7, and 13.5 after LASV challenge
(Figure 5). Significant increases in levels of IL-6 and IL-1b
were detected at day 13.5 (Figure 5). Increased levels of
IFN-a,I F N - g, IL-1R, IL-2R, IL-4, IL-5, IL-7, IL-8, IL-10,
IL-12 p40/p70, IL-13, IL-15, IL-17, IP-10, GM-CSF, MIG,
RANTES, and TNF-a were not detected in any animal at
a n yt i m ep o i n t .
Table 1 Clinical findings in cynomolgus monkeys infected with Lassa virus*
Days Postinfection Fever Rash Bleeding Anorexia Dehydration Recumbency
0 0/6 0/6 0/6 0/6 0/6 0/6
3 4/6 0/6 0/6 0/6 0/6 0/6
5.5 2/6 0/6 0/6 0/6 0/6 0/6
7 2/3 0/3 1/3 0/3 0/3 0/3
10 2/3 0/3 2/3 3/3 3/3 0/3
13 0/1 0/1 0/1 1/1 1/1 1/1
13.5 0/2 0/2 0/2 2/2 2/2 0/2
15 0/1 1/1 0/1 1/1 1/1 1/1
17 0/1 0/1 1/1 1/1 1/1 1/1
*Data are presented as the number of animals in which a clinical finding was observed followed by the total number of animals examined. Fever and
dehydration were evaluated in animals anesthetized for phlebotomy and/or physical examination. Rash, bleeding, anorexia, and recumbency were monitored in
all remaining animals at the specified time point.
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Figure 1 Hematology and coagulation values after infection of
cynomolgus monkeys with Lassa virus. Development of
lymphopenia (top left panel) and thromobocytopenia (top right panel).
Increases in circulating levels of D-dimers (bottom left panel) and
decreases in circulating levels of activated protein C (bottom right
panel).
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Page 4 of 15Histology and immunohistochemistry
Temporal results of LASV-infected cells demonstrated
in primary target tissues by immunohistochemistry are
shown in Table 2.
Lymphoid tissues
Lymph nodes LASV antigen was frequently detected in
dendritic cells of all lymph nodes of all animals (3/3) at
day 7 and rarely detected in endothelial cells of 2/3 ani-
mals at day 7. Sinus histiocytosis and mild lymphocytoly-
sis was seen in some, but not all lymph nodes in the
three animals euthanized at this time point. By terminal
time points (days 13.5-17) there was less extensive immu-
nopositive staining of dendritic cells in all lymph nodes of
all three animals. Increased numbers of immunopositive
endothelial cells were detected in all lymph nodes of all
terminal animals (3/3) (Figure 6A). An increase in
TUNEL-positive lymphocytes and scattered tingible body
macrophages with cytoplasmic TUNEL-positive debris
was observed in the axillary lymph node of 1/3 terminal
animals (Figure 6D) when compared with day 7 animals
(Figure 6C). However, TUNEL results from inguinal and
mesenteric lymph nodes were inconclusive.
Spleen At day 7, LASV immunostaining was noted in
cells morphologically consistent with dendritic cells pri-
m a r i l yi nt h em a r g i n a lz o n e( F i g u r e6 B )a n dt oal e s s e r
extent in monocytes and tissue macrophages in the mar-
ginal zones and red pulp. Mild lymphocytolysis was
noted in 2/3 animals. PTAH staining demonstrated infre-
quent deposition of polymerized fibrin in the red pulp
and marginal zone of 1/3 animals at this time point. By
terminal time points (days 13.5-17) LASV immunoposi-
tive dendritic cells were detected in spleen of all animals
(3/3) (Figure 6E) but were less frequently observed than
in day 7 animals. Increased numbers of immunopositive
endothelial cells were detected in spleen of all terminal
animals (3/3). Splenic lymphocytes were consistently
LASV immunonegative in all animals at all time points
(6/6). There appeared to be a slight increase in TUNEL-
positive lymphocytes and scattered tingible body macro-
phages with cytoplasmic TUNEL-positive debris in the
terminal animals (3/3). Detection of polymerized fibrin by
PTAH staining was occasionally present in the red pulp
and marginal zones of terminal animals (3/3) (Figure 7A)
with deposits being most prominent in the animal that
succumbed on day 15.
Thymus At day 7, LASV antigen distribution and
pathology was similar to that described for lymph nodes
and spleen with frequent immunostaining of dendritic
cells (Figure 6F). By terminal time points marked atro-
phy was apparent in all three animals (3/3).
Liver Histologically, the severity of hepatic changes var-
ied between animals at day 7. The most noteworthy
lesions were lymphoplasmacytic and neutrophilic
inflammation (2/3) (Figure 8A). LASV antigen was
detected in Kupffer cells and hepatocytes (3/3) at day 7
(Figure 8C). Lymphoplasmacytic and neutrophilic
inflammation was more pronounced in the terminal ani-
mals (3/3) (Figure 8B). LASV immunostaining increased
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Figure 2 Clinical chemistry values after infection of cynomolgus
monkeys with Lassa virus. Elevated levels of serum enzymes
primarily at the late stages of disease (days 13-17). Top left panel,
alanine aminotransferase (ALT). Top right panel, aspartate
aminotransferase (AST). Bottom left panel, blood urea nitrogen (BUN).
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Page 5 of 15Figure 3 Representative gross necropsy lesions from nonhuman primates experimentally infected with Lassa virus.( A) Enlargement and
moderate congestion of mesenteric lymph nodes (arrows) at day 15. (B) Accumulation of fluid in the pericardial cavity of a cynomolgus monkey
17 days after infection with Lassa virus. (C) Reticulation and discoloration of the liver 15 days after infection with Lassa virus. (D) Multifocal red
foci that microscopically corresponded with inflammation on the mucosal surface of the urinary bladder at day 15. (E) Congestion/hemorrhage
of the cecum occurring at day 15. The cecum is opened up and the ileum extends outward from the cecum; arrow indicates the ileocecal
junction.
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Page 6 of 15substantially at terminal time points (Figure 8D) with
increased numbers of immunopositive hepatocytes (3/3).
PTAH staining demonstrated multifocal distribution of
small fibrin deposits in sinusoids (Figure 7B) and vessels
(Figure 7C).
Endocrine system No significant lesions were detected
in the adrenal glands or pancreas at day 7. However,
s m a l lf o c io fL A S V - p o s i t i v eadrenal cortical cells were
detected in the zona glomerulosa and zona fasciculata of
2/3 animals (Figure 8E). By terminal time points there
was multifocal necrosis of adrenal cortical cells in all
animals (3/3). LASV immunostaining increased substan-
tially at terminal time points (Figure 8F) with increased
numbers of immunopositive adrenal cortical cells in all
zones (3/3). In addition, LASV antigen was occasionally
detected in pancreatic islets of 2/3 terminal macaques.
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Page 7 of 15Reproductive organs At day 7, histiocytic inflammation
was noted in ovaries and uterus of 1/3 animals. LASV
antigen was associated with histiocytes in these inflam-
matory foci. In addition, there was infrequent LASV
immunoreactivity of thecal cells surrounding ovarian fol-
licles in 2/3 animals at this time point. By terminal time
points, lymphoplasmacytic and histiocytic inflammation
was a prominent finding in the ovaries of 2/3 animals
immunoreactivity of granulosa cells. LASV antigen was
associated with histiocytes in these inflammatory foci and
granulosa cells near these areas of inflammation. Lym-
phocytic and histiocytic inflammation was noted in the
uterus and there was multifocal strong immunoreactivity
for LASV in uterine endothelial cells (3/3).
Kidneys and urinary bladder No significant renal or
bladder lesions were observed at day 7. Likewise, LASV
was rarely detected in interstitial and medullary capil-
laries at this time point (1/3). At terminal time points,
lymphoplasmacytic and neutrophilic inflammation was
observed in multiple foci of kidney of all animals (3/3).
LASV-positive endothelial cells were randomly scattered
throughout the kidney and surrounding connective tis-
sue (3/3). Multifocal lymphoplasmacytic and histiocytic
inflammation were noted in the bladder of 2/3 terminal
animals. Immunopositive transitional epithelial cells,
fibroblasts, and endothelial cells were also detected in
the bladder of 2/3 terminal animals. PTAH-positive
fibrin was multifocally detected in medullary vessels in
kidney of all terminal animals (3/3) (Figure 7D) with
deposits being most prominent in the animal that suc-
cumbed on day 15.
Lung No significant pulmonary lesions were noted at day
7. At terminal time points one animal (1/3) had mild
interstitial pneumonia. LASV antigen was detected multi-
focally in endothelial cells (3/3) and macrophages (1/3).
Heart Lesions at day 7 included histiocytic and neutro-
philic inflammation of the myocardium (1/3). LASV anti-
gen was detected in histiocytic inflammatory cells of this
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Figure 5 Cytokines and chemokines. Analysis of cytokine and chemokine accumulation in serum/plasma Lassa virus-infected cynomolgus
monkeys.
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Page 8 of 15animal. By the terminal time points, lesions were more
prominent and included plasmacytic and histiocytic
inflammation of the myocardium (3/3) and necrotizing
coronary arteritis (1/3). LASV antigen was detected in
histiocytic inflammatory cells (3/3) and vascular smooth
muscle cells (1/3) at this time point.
Nervous system No significant lesions were observed in
the nervous system at day 7. However, LASV immunos-
taining was infrequently detected in circulating histiocy-
tic cells (2/3) and in endothelial cells (2/3) at this
timepoint. Substantial changes in lesions and the pre-
sence of LASV occurred in the neuropil by terminal
time points. Noteworthy findings in terminal animals
included: meningoencephalitis in the cerebrum, cerebel-
lum (Figure 9A), and brainstem (3/3); neuronal necrosis
and gliosis in cerebrum (Figure 9B) and brainstem (3/3);
choroid plexitis (1/3); meningomyelitis (1/3); and neuri-
tis of optic nerve (2/3) (Figure 9C). LASV antigen was
detected multifocally in endothelial cells and histiocytic
inflammatory cells of cerebrum (Figures 9D,E), cerebel-
lum, brainstem, spinal cord, and optic nerve (Figure 9C)
of terminal animals. In addition, LASV antigen was
detected in glial cells in cerebrum of 2/3 animals and in
choroid plexis epithelial cells in cerebrum of 1/3 animals
(Figure 9F).
Discussion
Despite an estimated 3,000 fatal cases of LF per year in
West Africa [1], there have been relatively few postmortem
histologic or immunohistochemical studies [14,36-43].
Morphologic features from these cases include hepatic and
adrenal necrosis, splenic necrosis centered in the marginal
zone, mild myocarditis, mild interstitial pneumonia, and
lymphoid depletion. Interestingly, the extent of lesions
observed in any of these tissues is insufficient to account
for death. Histologic evaluation of terminal tissues from
LASV-infected macaques in the current study and previous
studies [19,20,34] mirrored these observations from human
cases. In addition, LASV infection of cynomolgus maca-
ques in the current study produced multifocal to severe
neuropathology at terminal stages of disease that was char-
acterized by central nervous system lesions associated with
LASV antigen. These findings are consistent with neurolo-
gic complications described in human LF including confu-
sion, tremor, seizure, convulsion, and coma which occur
frequently in critically ill patients who often succumb after
the onset of these symptoms [40,44,45].
Coagulations disorders, which are hallmark features of
viral HF do not appear to be as prominent in the major-
ity of cases of human LF [14,26,41]. For example, while
thrombocytopenia appears to be a consistent finding
among HF virus infections of humans and nonhuman
primates it is not a prominent feature of LASV infection
of humans or nonhuman primates [14,22,23,26,41].
Moderate thrombocytopenia was reported in patients
with severe LF, but the most significant changes were
noted in platelet function which was markedly depressed
in patients and in LASV-infected nonhuman primates
[24,26]. Overall, increased circulating levels of D-dimers
and slight decreases in plasma levels of protein C were
noted in the LASV-infected macaques in the current
study but these changes were modest compared to
changes reported in macaques infected with other HF
viruses such as Ebola [35]. However, hemorrhage has
been reported in a subset of LF patients and is asso-
ciated with high mortality [4,25,26]. Consistent with
human LF, LASV infection of nonhuman primates
appears to produce different degrees of coagulopathy in
individual animals with some animals showing more
severe coagulation disorders than others.
LASV infection of cynomolgus monkeys was character-
ized by a dysregulation of the host immune response. In
this study, we observed increased circulating levels of
proinflammatory cytokines/chemokines including IL-1b,
IL-6, MCP-1, and eotaxin. These results are consistent
with a previous study of LASV infection of macaques
which associated elevated levels of circulating IL-6 with
poor outcome [34]. In addition, our results for circulating
levels of cytokines/chemokines in LASV-infected macaques
Table 2 Immunohistochemical findings from cynomolgus
monkeys infected with Lassa virus
Animal
No.
Days
PI
Lymph nodes Spleen
Mono Mac Dend End Mono Mac Dend End
Subj 1 7 + + ++ + + + ++ -
Subj 2 7 + + +++ + + + +++ -
Subj 3 7 + + ++ + + + ++ -
Subj 4 13 + + + ++ + + + ++
Subj 5 15 + + + ++ + + + ++
Subj 6 17 + + + ++ + + + ++
Animal
No.
Days
PI
Liver/Adrenal Brain
Kup Hep Cort End Neur Glial Mac End
Subj 1 7 - + + - - - - +
Subj 2 7 ++ ++ ++ - - - + +
Subj 3 7 + + + - - - + -
Subj 4 13 ++ ++ +++ ++ - - ++ ++
Subj 5 15 ++ ++
+
+++ ++ - - ++ ++
Subj 6 17 ++ ++ +++ ++ - + ++ ++
+ indicates that LASV antigen-positive cells were rarely detected; + + indicates
that LASV-positive cells were occasionally detected; + + + indicates that LASV-
positive cells were frequently detected; and - indicates that no LASV-positive
cells were detected.
Mono = monocytes; Mac = macrophages; DC = dendritic cells; End =
Endothelial cells; Kup = Kupffer cells; Hep = hepatocytes; Cort = adrenal
cortical cells; Neur = Neurons.
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Page 9 of 15Figure 6 Immunohistochemistry and TUNEL staining in lymphoid tissues of cynomolgus monkeys.( A) Immunopositive endothelial cells
(brown) in an axillary lymph node at day 13. (B) Immunopositive tissue macrophages and dendritic cells (brown) in spleen at day 7. (C) TUNEL-
positive (brown) lymphocytes and scattered tingible body macrophages in an axillary lymph node at day 7. (D) TUNEL-positive (brown)
lymphocytes and scattered tingible body macrophages in an axillary lymph node at day 17. (E) Immunopositive tissue macrophages, endothelial
cells, and dendritic cells (brown) in spleen at day 13. Inset is enlargement of indicated area (arrow) showing dendritic cell. (F) Immunopositive
dendritic cells (brown) in thymus at day 7. Original magnifications, ×40 (A), ×20 (C, F), ×10 (B, D, F).
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Page 10 of 15were consistent with limited investigations of LASV-
infected patients. Specifically, Mahanty et al. showed high
levels of circulating IL-6 in fatal human cases of LF [46].
These investigators also reported that nonfatal LF is asso-
ciated with high levels of circulating IL-8 and IP-10. Con-
sistent with these findings we failed to detect any increases
in levels of IL-8 and IP-10 in moribund LASV-infected
cynomolgus monkeys.
A primary goal of the current study was to begin to
characterize the pathogenesis of LASV infection at times
before death. Evaluation of tissues by conventional histol-
ogy and immunohistochemistry demonstrated a consistent
pattern of LASV infection in cynomolgus monkeys start-
ing with dendritic cells in the lymphoid tissues progressing
to infection of Kupffer cells in liver and parenchymal cells
in liver and adrenal gland, endothelial cells in a variety of
tissues including nervous tissue, and finally to infection of
the epithelium. The prominent infection of dendritic cells
in all three LASV-infected cynomolgus macaques at day 7
is a particularly important finding. Dendritic cells were
also shown to be early targets of other HF viruses in non-
human primates [47]. Dendritic cells function as sentinels
of the adaptive immune system; they are located in the
peripheral tissues where they capture and process exogen-
ous antigens and migrate to regional lymph nodes where
they undergo maturation. Early infection of dendritic cells
likely plays a key role in the immunosuppression that is a
hallmark feature of LF in primates. Our in vivo findings
are consistent with previous in vitro studies demonstrating
that LASV infection of dendritic cells impairs their func-
tion and fails to activate the cells [48,49].
The sequence of morphological, cytologic, virologic,
serological, and inflammatory change following LASV in
cynomolgus monkeys creates a useful model in the
s t u d yo fL Fa n dp r o v i d e sab a s i cu n d e r s t a n d i n go ft h e
disease model and pathogenesis. This understanding is
critical for characterizing the LF nonhuman primate
model, identifying gaps in knowledge as well as identify-
ing critical pathways for validation with limited available
human data. This understanding and validation are
Figure 7 PTAH staining of Lassa virus-infected cynomolgus monkey tissues. Polymerized fibrin (arrows) in the marginal zone of spleen (A),
sinusoids (B) and vessels (C) in liver, and medullary vessels of the kidney (D) at day 15. Original magnifications, ×10 (D), ×20 (B), ×40 (A), ×60 (C).
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Page 11 of 15critical for the advancement of any prophylactic or ther-
apeutic product through the FDA under the Animal
Efficacy Rule.
Ethics
Research was conducted in compliance with the Animal
Welfare Act and other federal statutes and regulations
relating to animals and experiments involving animals
and adheres to principles stated in the Guide for the
Care and Use of Laboratory Animals, National Research
Council, 1996. The facility where this research was con-
ducted is fully accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care
International.
Figure 8 Histopathology and immunohistochemistry liver and adrenal gland of Lassa virus-infected cynomolgus monkeys. Histology of
liver showing inflammation at days 7 (A) and 15 (B); H&E stain. Note the progression of increased immunostaining (brown) of hepatocytes (C)
and adrenal cortical cells (E) from day 7 to day 15 (D, liver; F, adrenal gland). Original magnifications, ×10 (A, B, D, F), ×20 (C, E).
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Page 12 of 15Figure 9 Histopathology and immunohistochemistry of nervous tissue of Lassa virus-infected cynomolgus monkeys.( A) Histology of
cerebellum showing meningitis at day 15; H&E stain. (B) Histology of cerebrum showing neuronal necrosis at day 13; H&E stain. (C), Optic
neuritis; note immunopositive inflammatory foci (brown) at day 15. (D), Brain stem, immunopositive endothelium (arrow) and immunopositive
inflammatory foci (brown) in the neuropil peripheral to a medium-sized blood vessel at day 13. (E) Immunopositive endothelial cells (brown) in
cerebrum at day 15. (F) Choroid plexus, prominent immunostaining (brown) of the cuboidal epithelial cells lining the choroid at day 15. Original
magnifications, ×20 (B-F), ×40 (A)
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